BioMarin acquires Zacharon for $10mm in cash, plus earn-outs
Executive Summary
To help strengthen its development of drug candidates for lysosomal storage diseases (LSDs), BioMarin Pharmaceutical Inc. (rare disease therapies) is buying glycobiology specialist Zacharon Pharmaceuticals Inc. for $10mm in cash plus up to $134mm in earn-outs based on clinical, regulatory, and commercial achievements.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice